
Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.

Dr Sundarakrishnan is a business analyst at Lifescience Dynamics in Toronto, with experience conducting competitive intelligence analysis across oncology, hematology, immunology, and neuroscience. She earned her PhD from McGill University, where her research focused on modeling depression-related states in rodents.

Phase 3 psilocybin and LSD data plus new FDA guidance fuel a depression boom—yet clinics still wrestle with dosing time, cost, access.